keyword
MENU ▼
Read by QxMD icon Read
search

neutropenic fever

keyword
https://www.readbyqxmd.com/read/29616457/presepsin-as-a-diagnostic-marker-of-bacterial-infections-in-febrile-neutropenic-pediatric-patients-with-hematological-malignancies
#1
Ahmad Baraka, Marwa Zakaria
Febrile neutropenia (FN) is often observed in hematological malignancies (HEM). Presepsin is also known as soluble CD14 subtype; it is a glycoprotein fragment derived from monocytes and macrophages. We aimed to evaluate the significance of presepsin and other biomarkers for diagnosis of bacteremia in children with HEM. Sixty pediatric patients with different HEM (acute lymphoblastic leukemia 36, acute myeloid leukemia 12, non-Hodgkin lymphoma 10, and Hodgkin disease 2). Thirty age and sex-matched healthy children serving as control were enrolled in this study...
April 3, 2018: International Journal of Hematology
https://www.readbyqxmd.com/read/29608680/extended-versus-bolus-infusion-of-broad-spectrum-%C3%AE-lactams-for-febrile-neutropenia-an-unblinded-randomized-trial
#2
Ron Ram, Yael Halavy, Odelia Amit, Yael Paran, Eugene Katchman, Bruria Yachini, Svetlana Kor, Irit Avivi, Ronen Ben-Ami
Background: Febrile neutropenia may be a sign of severe infection, and is associated with significant morbidity and mortality in high-risk patients with hematologic malignancies. Extended infusion of β-lactam antibiotics is associated with greater clinical response than is bolus infusion in non-neutropenic critically ill patients, but data are lacking for febrile neutropenic patients. Methods: We designed a single-center, non-blinded randomized trial comparing extended infusion (4 hours) and bolus infusion (30 minutes) of piperacillin-tazobactam or ceftazidime in high-risk patients with febrile neutropenia...
March 28, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29589346/-recommendations-for-diagnostics-and-therapy-of-children-with-cancer-presenting-with-fever-and-neutropenia-comparison-of-two-current-guidelines
#3
Thomas Lehrnbecher, Andreas Groll, Philipp Agyeman, Roland A Ammann, Andishe Attarbaschi, Uta Behrends, Christoph Berger, Axel Hamprecht, Markus Hufnagel, Hans-Jürgen Laws, Max Scheler, Christian Temme, Simon Vieth, Arne Simon
Immunocompromised children and adolescents receiving treatment for cancer have a considerably increased risk for infection. Neutropenia is the most important single risk factor for infectious complications, and fever in neutropenia is considered as an emergency. Whereas guidelines for the management of fever in neutropenic adults have been established for decades, specific pediatric guidelines have not been developed until recently. As children differ in many aspects from adults such as in the underlying malignancy or in the availability and dosing of antimicrobial compounds, guidelines for pediatric patients are important...
March 27, 2018: Klinische Pädiatrie
https://www.readbyqxmd.com/read/29564621/addition-of-doxycycline-to-ciprofloxacin-for-infection-prophylaxis-during-autologous-stem-cell-transplants-for-multiple-myeloma
#4
J M Sivik, J Davidson, C M Hale, J J Drabick, G Talamo
BACKGROUND: The most commonly used antibacterial prophylaxis during autologous stem cell transplants (ASCT) for multiple myeloma (MM) involves a fluoroquinolone, such as ciprofloxacin or levofloxacin. We assessed the impact of adding doxycycline to ciprofloxacin as routine antibacterial prophylaxis in these patients. METHODS: We retrospectively reviewed electronic medical records and our ASCT database to analyze rates and types of bacterial infections in MM patients who underwent ASCT in our institution...
March 21, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29550383/liposomal-grb2-antisense-oligodeoxynucleotide-bp1001-in-patients-with-refractory-or-relapsed-haematological-malignancies-a-single-centre-open-label-dose-escalation-phase-1-1b-trial
#5
Maro Ohanian, Ana Tari Ashizawa, Guillermo Garcia-Manero, Naveen Pemmaraju, Tapan Kadia, Elias Jabbour, Farhad Ravandi, Gautam Borthakur, Michael Andreeff, Marina Konopleva, Miranda Lim, Sherry Pierce, Susan O'Brien, Yesid Alvarado, Srdan Verstovsek, William Wierda, Hagop Kantarjian, Jorge Cortes
BACKGROUND: Activating mutations of tyrosine kinases are common in leukaemias. Oncogenic tyrosine kinases use the growth factor receptor-bound protein 2 (Grb2) for signal transduction, leading to activation of mitogen-activated protein kinase (MAPK) 1 and MAPK3 (ERK2 and ERK1). We hypothesised that inhibition of Grb2 would suppress ERK1 and ERK2 activation and inhibit leukaemia progression. To inhibit Grb2, a liposome-incorporated antisense oligodeoxynucleotide that blocks Grb2 protein expression, BP1001, was developed...
April 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29531929/determination-relation-of-the-zinc-serum-level-in-acute-leukemia-adult-patients-with-mucositis-and-neutropenic-prevalence-before-and-after-treatment-in-isfahan-seyed-al-shohada-hospital-2012-2013
#6
Valiollah Mehrzad, Mehdi Mahmood-Zadeh, Awat Feizi, Arash Raisi
Background: Neutropenic fever and mucositis with 70% outbreak average is one of the major reasons of death in the acute leukemia adult patients. The aim of this study was to determine the relationship of serum zinc level with neutropenic fever and mucositis prevalence in acute leukemia adult patients and comparison of the effects of therapeutic intervention with the serum zinc correct level in the group of patients with zinc deficiency. Materials and Methods: From May 2012 to May 2013 in a double-blind, randomized, placebo-controlled study, on the basis of zinc serum level, 40 acute leukemia adult patients were divided into two groups of normal and deficiency zinc, and neutropenic fever and mucositis prevalence were taken into consideration in each and every group...
2018: Advanced Biomedical Research
https://www.readbyqxmd.com/read/29512471/tc-0-05-as-a-pharmacokinetic-parameter-of-paclitaxel-for-therapeutic-efficacy-and-toxicity-in-cancer-patients
#7
D S Xin, L Zhou, C Z Li, S Q Zhang, H Q Huang, G D Qiu, L F Lin, Y Q She, J T Zheng, C Chen, L Fang, Zhe-Sheng Chen, S Y Zhang
BACKGROUND: Paclitaxel (PTX) has remarkable anti-tumor activity, but it causes severe toxicities. There is an urgent need to seek an appropriate pharmacokinetic parameter of PTX to improve treatment efficacy and reduce adverse effects. OBJECTIVE: To evaluate the association of pharmacokinetic parameter TC>0.05 of paclitaxel (PTX) and its therapeutic efficacy and toxicity in patients with solid tumors. METHOD: A total of 295 patients with ovarian cancer, esophageal cancer, breast cancer, and non-small cell lung cancer (NSCLC), who were admitted to the Tumor Hospital of Shantou University Medical College, China, were recruited for this study...
March 5, 2018: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/29501780/clinical-impact-of-pretransplant-multidrug-resistant-gram-negative-colonization-in-autologous-and-allogeneic-hematopoietic-stem-cell-transplantation
#8
Alessandra Forcina, Francesca Lorentino, Vincenzo Marasco, Chiara Oltolini, Magda Marcatti, Raffaella Greco, Maria Teresa Lupo-Stanghellini, Matteo Carrabba, Massimo Bernardi, Jacopo Peccatori, Consuelo Corti, Fabio Ciceri
Multidrug-resistant Gram-negative bacteria (MDR-GNB) are an emerging cause of morbidity and mortality after hematopoietic stem cell transplantation (HSCT). Three-hundred forty-eight consecutive patients transplanted at our hospital from July 2012 to January 2016 were screened for a pretransplant MDR-GNB colonization and evaluated for clinical outcomes. A pretransplant MDR-GNB colonization was found in 16.9% of allo-HSCT and in 9.6% of auto-HSCT recipients. Both in auto- and in allo-HSCT, carriers of a MDR-GNB showed no significant differences in overall survival (OS), transplant-related mortality (TRM), or infection-related mortality (IRM) compared with noncarriers...
March 2, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29483801/evaluation-of-febrile-neutropenic-attacks-of-pediatric-hematology-oncology-patients
#9
Yeter Düzenli Kar, Zeynep Canan Özdemir, Özcan Bör
Aim: Febrile neutropenia is an important cause of mortality and morbidity in hematology-oncology patients undergoing chemotherapy. The objective of this study was to evaluate febrile neutropenic episodes in children with malignancy. Material and Methods: Sixty-eight children who received chemotherapy for malignancy between 2010 and 2015 were retrospectively reviewed. The demographic characteristics, laboratory data, infection foci, and frequency of microorganisms grown in culture were examined...
December 2017: Türk Pediatri Arşivi
https://www.readbyqxmd.com/read/29478800/granulocyte-transfusions-in-the-management-of-neutropenic-fever-a-pediatric-perspective
#10
REVIEW
Dilek Gurlek Gokcebay, Sibel Akpinar Tekgunduz
Severe neutropenia-associated invasive bacterial or fungal infections are still the major cause of mortality and morbidity in children receiving cancer chemotherapy. Granulocyte transfusion therapy has been used for many years in the management of neutropenic patients with severe infections in whom the clinical condition deteriorated despite appropriate antimicrobial treatment. Transfused granulocytes can increase the recipient's blood neutrophil count and accumulation of them into the site of infection. There are some data obtained from retrospective or prospective observational studies in pediatric granulocyte transfusion therapy, but results are not conclusive...
February 2018: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/29477362/evaluating-guideline-adherence-regarding-empirical-vancomycin-use-in-patients-with-neutropenic-fever
#11
Daniel B Chastain, Sarah Wheeler, Carlos Franco-Paredes, Babatunde Olubajo, W Anthony Hawkins
OBJECTIVE: The purpose of this study was to evaluate the use of empirical vancomycin for patients with neutropenic fever (NF) for adherence to treatment guidelines. METHODS: We identified adult patients with a diagnosis of neutropenia, who met the definition of NF as per treatment guidelines. Use of vancomycin was evaluated as part of empirical therapy and again, after 72hours. Outcomes were assessed using descriptive statistics, Chi square or Fisher's exact test, and univariate exact logistic regression analyses...
February 22, 2018: International Journal of Infectious Diseases: IJID
https://www.readbyqxmd.com/read/29464037/comparison-of-the-modified-low-dose-cytarabine-and-etoposide-with-decitabine-therapy-for-elderly-acute-myeloid-leukemia-patients-unfit-for-intensive-chemotherapy
#12
Seung-Hwan Shin, Byung-Sik Cho, Sung-Soo Park, Sung-Yeon Cho, Young-Woo Jeon, Jae-Ho Yoon, Seung-Ah Yahng, Sung-Eun Lee, Dong-Gun Lee, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong-Wook Lee, Woo-Sung Min, Hee-Je Kim
To overcome unsatisfactory results of classical low-dose cytarabine (LDAC) of cytarabine ≤20 mg twice daily (BID) subcutaneously for 10 days for patients with elderly acute myeloid leukemia (eAML), we evaluated a modified LDAC (mLDAC) of cytarabine 20 mg/m2 BID subcutaneously plus etoposide 50 mg BID orally for 14 days. To determine its feasibility, we compared outcomes of 77 and 42 eAML patients who received, respectively, mLDAC and decitabine (DAC; 20 mg/m2 intravenously daily for 5 days), which has shown better outcomes compared to those of classical LDAC...
January 19, 2018: Oncotarget
https://www.readbyqxmd.com/read/29456976/respiratory-viruses-in-febrile-neutropenic-patients-with-respiratory-symptoms
#13
Mohsen Meidani, Seyed Alireza Mirmohammad Sadeghi
Background: Respiratory infections are a frequent cause of fever in neutropenic patients, whereas respiratory viral infections are not frequently considered as a diagnosis, which causes high morbidity and mortality in these patients. Materials and Methods: This prospective study was performed on 36 patients with neutropenia who admitted to hospital were eligible for inclusion with fever (single temperature of >38.3°C or a sustained temperature of >38°C for more than 1 h), upper and lower respiratory symptoms...
2018: Advanced Biomedical Research
https://www.readbyqxmd.com/read/29451055/early-discontinuation-of-empirical-antibacterial-therapy-in-febrile-neutropenia-the-antibiostop-study
#14
Lenaïg Le Clech, Jean-Philippe Talarmin, Marie-Anne Couturier, Jean-Christophe Ianotto, Christophe Nicol, Ronan Le Calloch, Stéphanie Dos Santos, Pascal Hutin, Didier Tandé, Virginie Cogulet, Christian Berthou, Gaëlle Guillerm
INTRODUCTION: Immediate empirical antibiotic therapy is mandatory in febrile chemotherapy-induced neutropenia, but its optimal duration is unclear, especially in patients with fever of unknown origin (FUO). OBJECTIVES: The primary objective of this 20-month prospective observational study was to evaluate the feasibility and safety of short-term antibiotic treatment in afebrile or febrile patients exhibiting FUO, irrespective of their neutrophil count. The secondary objective was to describe the epidemiology of all episodes of febrile neutropenia...
February 16, 2018: Infectious Diseases
https://www.readbyqxmd.com/read/29448851/salvage-tigecycline-in-high-risk-febrile-neutropenic-patients-with-hematological-malignancies-a-prospective-multicenter-study
#15
Xin-Ping Zhou, Xiu-Jin Ye, Jian-Ping Shen, Jian-Ping Lan, Hui-Fang Jiang, Jin Zhang, Xue-Jin Zhang, Li Li, Shen-Xian Qian, Hong-Yan Tong
The purpose of this prospective, multi-center study was to examine the efficacy and safety of tigecycline as empirical treatment in neutropenic patients with hematological malignancies who failed to respond to first-line antibiotics. A total of 125 patients with persistent fever (>72 h) despite first-line antibiotics received empirical treatment with tigecycline (loading dose of 100 mg, followed by 50 mg every 12 h). The use of other antimicrobial agents was not restricted. Treatment success rate was 68...
February 16, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29392450/a-phase-i-study-of-intravenous-artesunate-in-patients-with-advanced-solid-tumor-malignancies
#16
John F Deeken, Hongkun Wang, Marion Hartley, Amrita K Cheema, Brandon Smaglo, Jimmy J Hwang, Aiwu Ruth He, Louis M Weiner, John L Marshall, Giuseppe Giaccone, Stephen Liu, Jim Luecht, Jay Y Spiegel, Michael J Pishvaian
PURPOSE: The artemisinin class of anti-malarial drugs has shown significant anti-cancer activity in pre-clinical models. Proposed anti-cancer mechanisms include DNA damage, inhibition of angiogenesis, TRAIL-mediated apoptosis, and inhibition of signaling pathways. We performed a phase I study to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of intravenous artesunate (IV AS). METHODS: Patients were enrolled in an accelerated titration dose escalation study with planned dose levels of 8, 12, 18, 25, 34 and 45 mg/kg given on days 1 and 8 of a 21-day cycle...
March 2018: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29376210/first-in-human-phase-i-dose-escalation-study-of-mk-8033-in-patients-with-advanced-solid-tumors
#17
Vicki L Keedy, Heinz-Josef Lenz, Leonard Saltz, Jennifer G Whisenant, Jordan D Berlin, Luis H Camacho
Background C-Met, which is frequently activated in multiple cancers, has been implicated in tumor formation, progression, metastasis, angiogenesis, and resistance to multiple therapies. MK-8033 is a small-molecule inhibitor of c-Met that binds preferentially to the activated conformation, and has demonstrated anti-tumor activity in preclinical models. This first-in-human trial was performed to establish the safety and maximum tolerated dose (MTD), as well as preliminary pharmacokinetics (PK) and clinical activity...
January 29, 2018: Investigational New Drugs
https://www.readbyqxmd.com/read/29349917/risk-stratification-for-febrile-neutropenia-in-patients-with-testicular-germ-cell-tumors
#18
Angelika Terbuch, Florian Posch, Richard Partl, Brigitte Zurl, Thomas Bauernhofer, Martin Pichler, Joanna Szkandera, Georg C Hutterer, Karl Pummer, Karin S Kapp, Herbert Stöger, Armin Gerger, Michael Stotz
The aim of this study was to detect risk factors for febrile neutropenia (FN) in patients with testicular germ cell tumors (TGCT). In this retrospective cohort study at the Medical University of Graz, we included 413 consecutive TGCT patients who received adjuvant or curative treatment with cisplatin-based chemotherapy. FN occurred in 70 (16.9%) of 413 patients. In univariable logistic regression, higher age (odds ratio (OR) per 5 years = 1.17, 95% CI: 1.02-1.35, P = 0.022), reduced performance status (PS) (OR = 2...
February 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29324209/using-process-improvement-tools-to-improve-the-care-of-patients-with-neutropenic-fever-in-the-emergency-room
#19
Avantika Dang, Lauren N Gjolaj, Myka Whitman, Gustavo Fernandez
PURPOSE: The purpose of this study was to improve the care of patients with neutropenic fever in an academic acute care hospital's emergency room (ER). METHODS: Using the define, measure, analyze, improve, control method, a two-phase project with three critical to quality metrics (reduction in time to antibiotic administration, increase in percentage of patients with neutropenic fever identified as an oncology emergency, and increase in patients cohorted on oncology units) was completed...
January 2018: Journal of Oncology Practice
https://www.readbyqxmd.com/read/29322242/utility-of-fosfomycin-as-antibacterial-prophylaxis-in-patients-with-hematologic-malignancies
#20
Tanya Zapolskaya, Sarah Perreault, Dayna McManus, Jeffrey E Topal
PURPOSE: Prolonged and profound neutropenia is common among hematology and hematopoietic stem cell transplant (HSCT) patients as a result of chemotherapy. The National Comprehensive Cancer Network (NCCN) and Infectious Diseases Society of America (IDSA) currently recommend antibacterial prophylaxis in patients who are deemed at intermediate or high risk for infection. Specifically, fluoroquinolone prophylaxis should be considered for high-risk neutropenic patients. However, with prolonged and frequent exposure to fluoroquinolones, these high-risk patients may develop resistance to these agents...
January 10, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
keyword
keyword
45469
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"